Vanguard Group’s Aspen Aerogels ASPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$13.3M Buy
4,685,950
+175,580
+4% +$905K ﹤0.01% 2818
2025
Q3
$31.4M Buy
4,510,370
+22,686
+0.5% +$160K ﹤0.01% 2398
2025
Q2
$26.6M Buy
4,487,684
+114,525
+3% +$659K ﹤0.01% 2425
2025
Q1
$27.9M Buy
4,373,159
+12,913
+0.3% +$124K ﹤0.01% 2348
2024
Q4
$51.8M Buy
4,360,246
+226,251
+5% +$3.86M ﹤0.01% 2144
2024
Q3
$114M Buy
4,133,995
+118,603
+3% +$2.97M ﹤0.01% 1813
2024
Q2
$95.8M Buy
4,015,392
+395,690
+11% +$9.29M ﹤0.01% 1854
2024
Q1
$63.7M Buy
3,619,702
+175,906
+5% +$2.59M ﹤0.01% 2063
2023
Q4
$54.3M Sell
3,443,796
-2,091
-0.1% -$21.6K ﹤0.01% 2156
2023
Q3
$29.6M Buy
3,445,887
+14,013
+0.4% +$99.5K ﹤0.01% 2378
2023
Q2
$27.1M Sell
3,431,874
-3,989
-0.1% -$27.8K ﹤0.01% 2460
2023
Q1
$25.6M Buy
3,435,863
+274,413
+9% +$2.73M ﹤0.01% 2485
2022
Q4
$37.3M Buy
3,161,450
+1,300,874
+70% +$14.9M ﹤0.01% 2329
2022
Q3
$17.2M Buy
1,860,576
+419,657
+29% +$5.08M ﹤0.01% 2700
2022
Q2
$14.2M Sell
1,440,919
-92,372
-6% -$1.86M ﹤0.01% 2808
2022
Q1
$52.9M Sell
1,533,291
-22,999
-1% -$746K ﹤0.01% 2278
2021
Q4
$77.5M Buy
1,556,290
+155,733
+11% +$8.21M ﹤0.01% 2120
2021
Q3
$64.4M Buy
1,400,557
+96,094
+7% +$3.81M ﹤0.01% 2225
2021
Q2
$39M Buy
1,304,463
+104,143
+9% +$2.13M ﹤0.01% 2497
2021
Q1
$24.4M Buy
1,200,320
+31,461
+3% +$664K ﹤0.01% 2677
2020
Q4
$19.5M Buy
1,168,859
+145,870
+14% +$1.92M ﹤0.01% 2645
2020
Q3
$11.2M Sell
1,022,989
-144,396
-12% -$1.14M ﹤0.01% 2732
2020
Q2
$7.68M Buy
1,167,385
+50,856
+5% +$326K ﹤0.01% 2892
2020
Q1
$6.86M Buy
1,116,529
+223,540
+25% +$1.81M ﹤0.01% 2806
2019
Q4
$6.93M Buy
892,989
+105,299
+13% +$727K ﹤0.01% 3036
2019
Q3
$4.66M Buy
787,690
+111,176
+16% +$707K ﹤0.01% 3161
2019
Q2
$4.82M Buy
676,514
+248,100
+58% +$1.13M ﹤0.01% 3181
2019
Q1
$1.09M Buy
428,414
+145,300
+51% +$432K ﹤0.01% 3604
2018
Q4
$603K Sell
283,114
-502,229
-64% -$1.7M ﹤0.01% 3691
2018
Q3
$3.59M Buy
785,343
+2,500
+0.3% +$12.2K ﹤0.01% 3347
2018
Q2
$3.84M Buy
782,843
+5,317
+0.7% +$25.2K ﹤0.01% 3293
2018
Q1
$3.32M Buy
777,526
+194,984
+33% +$922K ﹤0.01% 3294
2017
Q4
$2.84M Sell
582,542
-447
-0.1% -$2.08K ﹤0.01% 3313
2017
Q3
$2.54M Buy
582,989
+300
+0.1% +$1.31K ﹤0.01% 3333
2017
Q2
$2.59M Buy
582,689
+3,158
+0.5% +$13.3K ﹤0.01% 3303
2017
Q1
$2.4M Buy
579,531
+13,784
+2% +$58.7K ﹤0.01% 3325
2016
Q4
$2.34M Sell
565,747
-18,076
-3% -$88.1K ﹤0.01% 3315
2016
Q3
$3.48M Buy
583,823
+17,728
+3% +$89.3K ﹤0.01% 3169
2016
Q2
$2.81M Buy
566,095
+4,062
+0.7% +$17.8K ﹤0.01% 3236
2016
Q1
$2.53M Buy
562,033
+266,728
+90% +$1.21M ﹤0.01% 3292
2015
Q4
$1.79M Buy
295,305
+33,168
+13% +$230K ﹤0.01% 3434
2015
Q3
$1.97M Buy
262,137
+17,166
+7% +$125K ﹤0.01% 3385
2015
Q2
$1.62M Buy
244,971
+105,952
+76% +$725K ﹤0.01% 3502
2015
Q1
$1.01M Buy
139,019
+12,180
+10% +$92.2K ﹤0.01% 3629
2014
Q4
$1.01M Buy
126,839
+2,891
+2% +$24.5K ﹤0.01% 3528
2014
Q3
$1.25M Sell
123,948
-1,952
-2% -$19.8K ﹤0.01% 3444
2014
Q2
$1.39M Buy
+125,900
New +$1.37M ﹤0.01% 3391

Other funds holding ASPN

Vanguard Group's ASPN Position: Q4 2025 in Review

Vanguard Group increased its Aspen Aerogels (ASPN) stake by 3.9% in Q4 2025, buying an estimated $905K and bringing the position to 4,685,950 shares worth $13.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2818.

Vanguard Group first reported a position in ASPN in Q2 2014 and has held it in 47 quarters since. The position peaked at $114M in Q3 2024. 183 funds tracked by Wall St. Rank hold ASPN as of Q4 2025.

  • Vanguard Group held 4,685,950 shares of Aspen Aerogels worth $13.3M as of Q4 2025.
  • Vanguard Group bought 175,580 Aspen Aerogels shares in Q4 2025, an estimated $905K.
  • Aspen Aerogels made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2818 holding.
  • Vanguard Group first reported a position in Aspen Aerogels in Q2 2014 and has held it in 47 quarters since.
  • Vanguard Group's Aspen Aerogels position peaked at $114M in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Aspen Aerogels as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.